Ritanserin facilitates anxiety in a simulated public-speaking paradigm

Journal of Psychopharmacology

Volumn 11, Issue 3, 1997, Pages 225-231

  Guimaraes F S ^a   Mbaya, P S ^b   Deakin, J F W ^b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

5 HT2 receptors; Anxiety; Public speaking; Ritanserin

Indexed keywords

RITANSERIN; SEROTONIN 2A ANTAGONIST;

ADULT; ANXIETY; ANXIETY NEUROSIS; ARTICLE; AUTONOMIC NERVOUS SYSTEM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; FEMALE; HEART RATE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PULSE RATE; SEDATION; SKIN CONDUCTANCE; SPEECH;

ADOLESCENT; ADULT; ANTI-ANXIETY AGENTS; ANXIETY; FEMALE; HUMANS; MALE; RECEPTORS, SEROTONIN; RITANSERIN; SEROTONIN ANTAGONISTS; VERBAL BEHAVIOR;

EID: 0030833355     PISSN: 02698811     EISSN: None     Source Type: Journal    
DOI: 10.1177/026988119701100305     Document Type: Article

References (35)

1. Adell A, Artigas F (1991) Differential effects of clomipramine given locally or systematically on extracellular 5-hydroxytryptamine in raphé nuclei and frontal cortex. Archs Pharmac 342: 237-244
2. Blier P, de Montigny C, Chaput Y (1987) Modifications of the serotonin system by antidepressant treatments: implications for the therapeutic response in major depression. J Clin Psychopharmac 7: 245-355
3. Bond A J, Lader M H (1974) The use of analogue scales in rating subjective feelings. Br J Med Psychol 47: 211-218
4. Ceulemans D K S, Hoppenbrouwers M-L J A, Gelders Y G, Reyntjens A J M (1985) The influence of ritanserin, a serotonin antagonist, in anxiety disorders: a double-blind placebo-controlled study versus lorazepam. Pharmacopsychiatry 18: 303-305
5. Charney D S, Woods S W, Goodman W K, Rifkin B, Kinch M, Aiken B, Quandrino L M, Heninger G R (1986) Drug treatment of panic disorder: the comparative efficacy of imipramine, alprazolam and trazodone. J Clin Psychiat 47: 580-586
6. Davis M (1989) The role of the amygdala and its efferent projections in fear and anxiety. In Tyrer P (ed.), Psychopharmacology of anxiety. Oxford University Press, Oxford, pp. 52-79
7. Davis M (1990) Animal models of anxiety based on classical conditioning: the conditioned emotional response (CER) and the fear-potentiated startle reflex. Pharmac Therap 47: 147-165
8. Deakin J F W (1983) Roles of serotonergic systems in escape, avoidance and other behaviours. In Cooper S J (ed.), Theory in psychopharmacology. Academic Press, New York, pp. 149-193
9. Deakin J F W (1988) 5HT2 receptors in depression and anxiety. Pharmac, Biochem Behav 29: 819-820
10. Deakin J F W (1989) 5HT receptor subtypes in depression. In Bevan P, Cools A R, Archer T (eds), Behavioural pharmacology of 5HT. Lawrence Erlbaum, Hillsdale, NJ, pp. 179-204
11. Deakin J F W, Graeff F G (1991) 5HT and mechanisms of defence. J Psychopharmac 5: 305-315
12. Deakin J F W, Guimarães F S, Wang M, Hellewell J S E, Hensman R (1991) 5HT receptor mechanisms in human anxiety. In Briley M, File S (eds), New concepts in anxiety. Macmillan Press, London, pp. 74-93
13. Den Boer J A, Westenberg H G M (1990) Serotonin function in panic disorder: a double blind placebo controlled study with fluvoxamine and ritanserin. Psychopharmacology 102: 85-94
14. Geer J H (1965) The development of a scale to measure fear. Behav Res Therap 3: 45-53
15. Graeff F G (1981) Minor tranquillizers and brain defense systems. Braz J Med Biol Res 14: 239-265
16. Graeff F G (1989) Serotonin and aversion. In Bevan P, Cools A R, Archer T (eds), Behavioural pharmacology of 5HT. Lawrence Erlbaum, London, pp. 425-443
17. Graeff F G, Zuardi A W, Giglio J S, Lima Filhoe E C, Karniol I G (1985) Effect of metergoline on human anxiety. Psychopharmacology 86: 334-338
18. Gray J A (1982) The neuropsychology of anxiety: an enquiry into the functions of the sept-hippocampal system. Behav Brain Sci 5: 469-484
19. Guimarães F S, Zuardi A W, Graeff F G (1987) Effect of chlorimipramine and maptrotiline on experimental anxiety in humans. J Psychopharmac 1: 184-192
20. Guimarães F S, Hellewell J S E, Hensman R, Wang M, Deakin J F W (1991) Characterisation of a psycho-physiological model of classical fear conditioning in healthy volunteers: influence of gender, instruction, personality and placebo. Psychopharmacology 104: 231-236
21. Hensman R, Guimarães F S, Wang M, Deakin J F W (1991) Effects of ritanserin on aversive classical conditioning in humans. Psychopharmacology 104: 220-224
22. Hetem L A B, De Souza C J, Guimarães F S G, Zuardi AW, Graeff F G (1993) D-fenfluramine reduces anxiety induced by simulated public speaking. Braz J Med Biol Res 26: 971-974
23. Hodges H, Green S, Glenn B (1987) Evidence that the amygdala is involved in benzodiazepine and serotonergic effects on punished responding but not in discrimination. Psychopharmacology 92: 491-504
24. Iversen S D (1984) 5HT and anxiety. Neuropharmacology 23: 1553-1560
25. Kahns R S, Asnis G M, Wetzler S, Van Praag H M (1988) Neuroendocrine evidence for serotonin receptor hypersensitivity in panic disorder. Psychopharmacology 96: 360-364
26. Kataoka Y, Schibata K, Yamashita K, Ueki S (1987) Differential mechanisms involved in the anticonflict action of benzodiazepines injected into the central amygdala and mammillary body. Brain Res 416: 243-247
27. LeDoux J E, Iwata J, Cichetti P, Reis D J (1988) Different projections of the central amygdaloid nucleus mediate autonomic and behavioural correlates of conditioned fear. J Neurosci 8: 2517-2529
28. McNair DM, Frankenthaler I M, Czerlinsky T, White T W, Sasson S, Fisher S (1982) Simulated public speaking as a model of clinical anxiety. Psychopharmacology 77: 7-10
29. Nashold J B S, Wilson N P, Slaughter G S (1969) Sensations evoked by stimulation in the midbrain of man. J Neurosurg 30: 14-24
30. Norris H (1971) The action of sedatives on brainstem oculomotor systems in man. Neuropharmacology 10: 181-191
31. Norusis M J (1988) SPSS/PC+ advanced statistics. SPSS, Chicago, IL
32. Petersen E N, Scheel-Krueger J (1984) Anticonflict effects of 5HT antagonists by intra-amygdaloid injection. 14th CINP Congress: 654
33. Spielberger C D, Gorsuch R L, Lushene R E (1970) Manual for the State-Trait Anxiety Inventory. Consulting Psychologists Press, Palo Alto, CA
34. Targun S D, Marshall L E (1989) Fenfluramine provocation of anxiety in patients with panic disorder. Psychiat Res 28: 295-306
35. Venables P H, Christie M J (1980) Electrodermal activity. In Martin I, Venables P H (eds), Techniques in psychophysiology. John Wiley, Chichester, pp. 3-68